GlaxoSmithKline's Arnuity approved for patients over the age of 12 as part of treatment options
The US Food and Drug Administration recently announced the approval of a new asthma drug.
GlaxoSmithKline’s (GSK) Arnuity (fluticasone furoate) works with the company’s dry-powder inhaler Ellipta. As the fourth drug to go with the inhaler, Arnuity was approved for once-daily use for asthma patients over the age of 12. It was not approved to be used for the treatment of acute bronchospasm.
Arnuity joins Breo, Anoro, and Incruse as another key part in the company’s asthma treatment franchise, according to Darrell Baker, GSK’s senior vice president of the company’s global respiratory franchise.
“It is the first asthma treatment from our new portfolio to have gained approval in the US and enables us to begin expanding the range of medicines that we offer to physicians and appropriate patients,” he said in a statement from the company.